Access
To read this story in full you will need to login or make a payment (see right).
Brief Communications
Nature 436, 642 (4 August 2005) | doi:10.1038/436642a
nature jobs
Research Associate / Scientist (Neuropharmacology)
- F. Hoffmann-La Roche AG
- Basel, 4000, Switzerland
Postdocs and PhD in computational nanoscience
- National Nanotechnology Laboratory of CNR-INFM
- Lecce, Italy
Tumour biology: Senescence in premalignant tumours
Manuel Collado1, Jesús Gil2, Alejo Efeyan1, Carmen Guerra1, Alberto J. Schuhmacher1, Marta Barradas1, Alberto Benguría3, Angel Zaballos3, Juana M. Flores4, Mariano Barbacid1, David Beach5 & Manuel Serrano1
Abstract
Oncogene-induced senescence is a cellular response that may be crucial for protection against cancer development1, 2, but its investigation has so far been restricted to cultured cells that have been manipulated to overexpress an oncogene. Here we analyse tumours initiated by an endogenous oncogene, ras, and show that senescent cells exist in premalignant tumours but not in malignant ones. Senescence is therefore a defining feature of premalignant tumours that could prove valuable in the diagnosis and prognosis of cancer.
To read this story in full you will need to login or make a payment (see right).
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Senescence comes of ageNature Medicine News and Views (01 Sep 2005)
Barriers to Ras transformationNature Cell Biology News and Views (01 May 2007)
See all 4 matches for News And ViewsRESEARCH
ATM?Chk2?p53 activation prevents tumorigenesis at an expense of organ homeostasis upon Brca1 deficiencyThe EMBO Journal Article (17 May 2006)
See all 30 matches for Research